Capecitabine named-patient programme for patients with advanced breast cancer: the UK experience

This publication has 11 references indexed in Scilit:

• Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
  Journal of Clinical Oncology, 2002
• First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
  Annals of Oncology, 2002
• Clinical experience of capecitabine in metastatic breast cancer
  European Journal Of Cancer, 2002
• Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
  Cancer, 2001
• Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial
  European Journal Of Cancer, 2001
• Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
  Cancer Chemotherapy and Pharmacology, 2000
• Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
  Expert Opinion on Pharmacotherapy, 2000
• Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients
  European Journal Of Cancer, 1999
• Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
  Journal of Clinical Oncology, 1999
• Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
  Published by Elsevier ,1998